Table 1.

Service user/PPI contributions and their impacts

Who was involved and howStage and contributionImpact
 Application development  
Nottingham Maternity Research Network (NMRN) members.
Three in-person meetings, chief investigator, patient and public involvement (PPI) Lead 
Discussion of:
  • rationale for the study

  • implications of anemia in pregnancy, what is important to women?

  • intervention and possible alternatives

  • experiences of anemia on quality of life

  • experiences of the treatment of anemia and side effects

  • experiences of follow-up of diagnosed anemia

  • importance of respecting women’s autonomy and choice: over-the-counter (OTC) liquid iron preparations

 
Study supported: NMRN to provide ongoing advice
Two NMRN members joined the research team and were named Service User Coinvestigators (SUCoIs).
Informed:
  • Trial design: no dietary advice arm

  • Inclusion criteria

  • Selection of outcome measures.

  • Development of clinical decision guide

  • Data item (use of OTC preparations)

 
 Planning, interpretation, and reporting of dose-finding study  
NMRN meetings, chief investigator, PPI Lead
SUCoIs
Project management group (PMG)
Written feedback 
Collection of self-reported data
Discussion of:
  • acceptability of different methods

  • avoiding burden for women

  • environmental impacts

 
  • Informed:

  • Plan for data collection

 
SUCoIs, PPI Lead
Written feedback
PMG 
Feedback on participant-facing materials and protocol:
  • participant information sheet (PIS)

  • consent form

  • medication adherence questionnaire (MARS-5)

 
  • Informed:

  • PIS content

  • MARS 5 included; reservations noted

 
SUCoIs
Feedback on analytical report
PMG
Written feedback on draft 
Interpretation of findings and relative emphasis of impacts on clinical measurements vs side effects
Output
Minutes 
Incorporated 
Trial Steering Committee (TSC) Trial oversight 
  • Independent public member of TSC

  • Public contribution in all aspects of trial governance

 
Who was involved and howStage and contributionImpact
 Application development  
Nottingham Maternity Research Network (NMRN) members.
Three in-person meetings, chief investigator, patient and public involvement (PPI) Lead 
Discussion of:
  • rationale for the study

  • implications of anemia in pregnancy, what is important to women?

  • intervention and possible alternatives

  • experiences of anemia on quality of life

  • experiences of the treatment of anemia and side effects

  • experiences of follow-up of diagnosed anemia

  • importance of respecting women’s autonomy and choice: over-the-counter (OTC) liquid iron preparations

 
Study supported: NMRN to provide ongoing advice
Two NMRN members joined the research team and were named Service User Coinvestigators (SUCoIs).
Informed:
  • Trial design: no dietary advice arm

  • Inclusion criteria

  • Selection of outcome measures.

  • Development of clinical decision guide

  • Data item (use of OTC preparations)

 
 Planning, interpretation, and reporting of dose-finding study  
NMRN meetings, chief investigator, PPI Lead
SUCoIs
Project management group (PMG)
Written feedback 
Collection of self-reported data
Discussion of:
  • acceptability of different methods

  • avoiding burden for women

  • environmental impacts

 
  • Informed:

  • Plan for data collection

 
SUCoIs, PPI Lead
Written feedback
PMG 
Feedback on participant-facing materials and protocol:
  • participant information sheet (PIS)

  • consent form

  • medication adherence questionnaire (MARS-5)

 
  • Informed:

  • PIS content

  • MARS 5 included; reservations noted

 
SUCoIs
Feedback on analytical report
PMG
Written feedback on draft 
Interpretation of findings and relative emphasis of impacts on clinical measurements vs side effects
Output
Minutes 
Incorporated 
Trial Steering Committee (TSC) Trial oversight 
  • Independent public member of TSC

  • Public contribution in all aspects of trial governance

 

or Create an Account

Close Modal
Close Modal